Table 1. Characteristics of studies investigating the effects of antithyroid drugs in Korean children with Graves disease

Reference	No. of patients	Age at diagnosis, years (mean, range)	Duration of ATD therapy, years (mean, range)	Duration of follow-up, years (mean)	ATD discontinuation rate, % (n)	Remission rate, % (n)	Relapse rate (among discontinuation group), % (n)	Predictors for remission
Lee et al., 2009 [26]	64	11.1 (3–16)	ND	8.1	67.2 (43/64)	57.8* (37/64)	37.2 (16/43)	Shorter time for TBII normalization
Song et al., 2010 [27]	113	12.6 (6–18)	4.5 (0.4–14.2)	6.6 (0.8–16.5)	66.4 (75/113)	55.8* (63/113)	20.4 (23/75)	Older age at diagnosis
Kim et al., 2012 [28]	42	11.5	4.3 (1.7–11.0) for remission group; 4.8 (2.0–9.4) for non-remission group	4.5	54.8 (23/42)	52.4* (22/42)	17.4 (4/23)	Lower TSH levels at diagnosis
Song et al., 2021 [29]	187	12.9	4.7	5.9	55.6 (104/187)	33.2* (62/187)	60.6 (63/104)	Lower FT4 at diagnosis
Rho et al., 2021 [30]	98	11.6 (2–16)	2.9 for remission group	All followed for 5 years	24.5 (24/98)	18.3 (18/98)	25.0 (6/24)	Lower TBII at diagnosis and follow-up;Shorter time for TBII normalization

ATD, antithyroid drug; ND, no data; TBII, thyroid-binding inhibitory immunoglobulin; TSH, thyroid-stimulating hormone; FT4, free thyroxine.
Remission rate after 1–3 courses of antithyroid drug treatment.